Abstract

Background and aims:¬†Oral small-molecule drugs (SMDs) are expanding the therapeutic landscape for inflammatory bowel disease (IBD). This systematic review and meta-analysis summarises the efficacy and safety of JAK inhibitor (JAKi) and sphingosine-1-phosphate (S1P) receptor modulator treatments for ulcerative colitis (UC) and Crohn’s disease (CD).

Tags

Inflammatory Bowel Disease, JAK inhibitors

Read More